ArticleCureus2025
Stevens-Johnson Syndrome as a Risk Factor for Ocular Surface Squamous Neoplasia in a Pediatric Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report describes a rare case of ocular surface squamous neoplasia (OSSN) developing in the aftermath of Stevens-Johnson syndrome (SJS). A 15-year-old female patient, who had previously experienced an episode of SJS triggered by non-steroidal anti-inflammatory drugs (NSAIDs), developed limbal stem cell deficiency (LSCD) and was subsequently diagnosed with OSSN in the setting of chronic ocular surface inflammation. She was treated successfully with topical immunotherapy using interferon alpha-2b. This case highlights the pivotal role of chronic inflammation and immune dysregulation in driving neoplastic transformation of the ocular surface. In particular, severe immune-mediated disorders such as SJS can disrupt corneal homeostasis and establish a pro-oncogenic microenvironment that fosters dysplasia and neoplastic progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.